Newsroom
Articles > Investor Alert: ADMA Biologics Faces Securities Class Action Lawsuits
- Faruqi & Faruqi, LLP reminds ADMA Biologics investors of the securities class action lawsuit deadline on August 10, 2026
- Pomerantz Law Firm announces class action lawsuit against ADMA Biologics with upcoming deadlines
- Kahn Swick & Foti, LLC notifies investors of class action securities lawsuit deadline for ADMA Biologics
- The Schall Law Firm reminds investors of a class action lawsuit against ADMA Biologics for securities violations
- Lowey Dannenberg P.C. investigates ADMA Biologics for potential federal securities laws violations
A series of law firms have issued alerts and reminders to ADMA Biologics investors regarding ongoing class action lawsuits against the Company. Faruqi & Faruqi, LLP is one of the leading national securities law firms investigating potential claims against ADMA Biologics, reminding investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. Those who suffered losses in ADMA Biologics between August 9, 2024 and March 25, 2026 are encouraged to contact partner James (Josh) Wilson directly to discuss their legal options.
Similarly, Pomerantz Law Firm has announced that a class action lawsuit has been filed against ADMA Biologics, advising investors who have faced losses on their investments to reach out to Danielle Peyton for further information. The firm reminds investors of the upcoming deadlines related to the lawsuit.
Kahn Swick & Foti, LLC, along with partner Charles C. Foti, Jr., has notified investors in ADMA Biologics of a class action securities lawsuit and the application deadline on August 10, 2026.
Moreover, The Schall Law Firm has encouraged investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 to contact the firm before the August 10, 2026 deadline. The firm is pursuing a class action lawsuit against the Company for violations of securities laws.
Furthermore, Lowey Dannenberg P.C., a top complex litigation law firm, is currently investigating ADMA Biologics for potential violations of federal securities laws. The firm is looking into allegations of misrepresentations about the Company's revenue sources that led to a significant stock plummet.
In light of these developments, it is crucial for ADMA Biologics investors to be aware of the ongoing legal actions and deadlines related to the securities class action lawsuits. Seeking legal counsel and understanding their rights is paramount for investors who may have suffered losses in the Company. Contacting the respective law firms mentioned in the alerts can provide investors with more information on how to proceed in this legal matter.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Investor Alert: ADMA Biologics Faces Securities Class Action Lawsuits
By KlickAnalytics Data Insights | June 30, 2026 08:04PM ET
Key Points
- Faruqi & Faruqi, LLP reminds ADMA Biologics investors of the securities class action lawsuit deadline on August 10, 2026
- Pomerantz Law Firm announces class action lawsuit against ADMA Biologics with upcoming deadlines
- Kahn Swick & Foti, LLC notifies investors of class action securities lawsuit deadline for ADMA Biologics
- The Schall Law Firm reminds investors of a class action lawsuit against ADMA Biologics for securities violations
- Lowey Dannenberg P.C. investigates ADMA Biologics for potential federal securities laws violations
A series of law firms have issued alerts and reminders to ADMA Biologics investors regarding ongoing class action lawsuits against the Company. Faruqi & Faruqi, LLP is one of the leading national securities law firms investigating potential claims against ADMA Biologics, reminding investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. Those who suffered losses in ADMA Biologics between August 9, 2024 and March 25, 2026 are encouraged to contact partner James (Josh) Wilson directly to discuss their legal options.
Similarly, Pomerantz Law Firm has announced that a class action lawsuit has been filed against ADMA Biologics, advising investors who have faced losses on their investments to reach out to Danielle Peyton for further information. The firm reminds investors of the upcoming deadlines related to the lawsuit.
Kahn Swick & Foti, LLC, along with partner Charles C. Foti, Jr., has notified investors in ADMA Biologics of a class action securities lawsuit and the application deadline on August 10, 2026.
Moreover, The Schall Law Firm has encouraged investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 to contact the firm before the August 10, 2026 deadline. The firm is pursuing a class action lawsuit against the Company for violations of securities laws.
Furthermore, Lowey Dannenberg P.C., a top complex litigation law firm, is currently investigating ADMA Biologics for potential violations of federal securities laws. The firm is looking into allegations of misrepresentations about the Company's revenue sources that led to a significant stock plummet.
In light of these developments, it is crucial for ADMA Biologics investors to be aware of the ongoing legal actions and deadlines related to the securities class action lawsuits. Seeking legal counsel and understanding their rights is paramount for investors who may have suffered losses in the Company. Contacting the respective law firms mentioned in the alerts can provide investors with more information on how to proceed in this legal matter.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.